Enovis (ENOV) Expected to Post Earnings on Thursday

Enovis (NYSE:ENOV) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Enovis to post earnings of $0.7670 per share and revenue of $557.12 million for the quarter. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Individuals may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. The company had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.79 earnings per share. On average, analysts expect Enovis to post $3.15 EPS for the current fiscal year and $3.08 EPS for the next fiscal year.

Enovis Stock Up 3.4%

ENOV stock opened at $20.59 on Tuesday. The company’s 50 day simple moving average is $19.91 and its 200-day simple moving average is $23.06. The firm has a market capitalization of $1.19 billion, a PE ratio of -1.07 and a beta of 1.37. Enovis has a 12 month low of $16.70 and a 12 month high of $32.41. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00.

Insider Transactions at Enovis

In other news, CEO Damien Mcdonald acquired 13,035 shares of Enovis stock in a transaction that occurred on Friday, September 4th. The shares were acquired at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the purchase, the chief executive officer owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This represents a 5.57% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Oliver Engert acquired 2,660 shares of Enovis stock in a transaction that occurred on Friday, September 4th. The shares were purchased at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the purchase, the insider directly owned 63,898 shares of the company’s stock, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 23,293 shares of company stock valued at $449,599. Insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

ENOV has been the subject of several research reports. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Wells Fargo & Company lowered their target price on Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, September 2nd. Citizens Jmp dropped their price target on Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. Citigroup reissued a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Finally, Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Enovis has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.